Literature DB >> 2569487

Differential steroid hormone and neural influences on peptide mRNA levels in CRH cells of the paraventricular nucleus: a hybridization histochemical study in the rat.

L W Swanson1, D M Simmons.   

Abstract

The three major classes of neurons in the paraventricular nucleus (PVH) provide a rich model for studying hormonal and neural influences on multiple neuropeptides expressed in individual cells. A great deal of previous work has examined this problem at the immunohistochemical level, where hormonal and neural influences on peptide levels have been established. In situ hybridization methods were used here to determine whether these effects are accompanied by measurable changes in neuropeptide mRNA levels. In the first series of experiments, the time-course of corticosterone replacement effects on corticotropin-releasing hormone (CRH) mRNA levels in parvicellular neuroendocrine cells of adrenalectomized animals were determined, and a dose-response curve was established. CRH mRNA hybridization remains maximal with plasma levels of steroid up to about 50 ng/ml, then declines sharply between about 60-130 ng/ml, and is just detectable at higher levels. We confirmed that corticosterone decreases vasopressin mRNA levels in this cell group and showed that levels of preproenkephalin mRNA are also decreased, whereas no significant changes in cholecystokinin, beta-preprotachykinin, and angiotensinogen mRNA levels could be detected. Thus, corticosterone decreases some neuropeptide mRNA levels and has no influence on others in this cell group. Tyrosine hydroxylase mRNA hybridization is also unaffected in this part of the nucleus. In a second group of experiments, the cell-type specificity of corticosterone influences was examined. It was found that while the hormone depresses CRH mRNA levels in parvicellular neurons, it increases such levels in PVH neurons with descending projections, in certain magnocellular neurosecretory neurons, and in a part of the central nucleus of the amygdala, whereas no influence was detected in the rostral lateral hypothalamic area. Furthermore, the stimulatory effects of corticosterone have different threshold levels in different cell groups. Thus, in different types of neurons, corticosterone may increase, decrease, or have no influence on CRH mRNA levels. In contrast, while corticosterone depresses vasopressin mRNA levels in parvicellular CRH neurons, it has no obvious effects on vasopressin mRNA levels in magnocellular or descending neurons; as with CRH, the effects of corticosterone on vasopressin mRNA levels are cell-type specific. In a third series of experiments it was shown that glucocorticoid receptor and mineralocorticoid receptor mRNAs are found in all three cell types in the PVH and that corticosterone tends to produce modest increases in mRNA levels for both receptors. Finally, it was shown that unilateral catecholamine-depleting knife cuts do not change mRNA levels for any of the neuropeptides (or steroid hormone receptors) examined here, although dramatic changes in neuropeptide levels themselves have been shown.4+

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2569487     DOI: 10.1002/cne.902850402

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  98 in total

Review 1.  Mapping biochemical signals in the brain.

Authors:  Jay Schulkin
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

Review 2.  Hippocampal neuroplasticity induced by early-life stress: functional and molecular aspects.

Authors:  Kristina A Fenoglio; Kristen L Brunson; Tallie Z Baram
Journal:  Front Neuroendocrinol       Date:  2006-04-17       Impact factor: 8.606

3.  A new module for on-line manipulation and display of molecular information in the brain architecture management system.

Authors:  Mihail Bota; Larry W Swanson
Journal:  Neuroinformatics       Date:  2006

4.  Treatment with CRH-1 antagonist antalarmin reduces behavioral and endocrine responses to social stressors in marmosets (Callithrix kuhlii).

Authors:  Jeffrey A French; Jeffrey E Fite; Heather Jensen; Katie Oparowski; Michael R Rukstalis; Holly Fix; Brenda Jones; Heather Maxwell; Molly Pacer; Michael L Power; Jay Schulkin
Journal:  Am J Primatol       Date:  2007-08       Impact factor: 2.371

Review 5.  Glucocorticoid inhibition in the treatment of depression: can we think outside the endocrine hypothalamus?

Authors:  Mitchel A Kling; Victoria H Coleman; Jay Schulkin
Journal:  Depress Anxiety       Date:  2009       Impact factor: 6.505

6.  Corticotropin-releasing factor, neuroplasticity (sensitization), and alcoholism.

Authors:  George F Koob
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-26       Impact factor: 11.205

Review 7.  Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies.

Authors:  Megan C Chapter; Caitlin M White; Angela DeRidder; Wayne Chadwick; Bronwen Martin; Stuart Maudsley
Journal:  Pharmacol Ther       Date:  2009-08-15       Impact factor: 12.310

8.  Absence of glucocorticoids augments stress-induced Mkp1 mRNA expression within the hypothalamic-pituitary-adrenal axis.

Authors:  Chad D Osterlund; Vanessa Thompson; Laura Hinds; Robert L Spencer
Journal:  J Endocrinol       Date:  2013-11-28       Impact factor: 4.286

9.  A novel mouse model for acute and long-lasting consequences of early life stress.

Authors:  Courtney J Rice; Curt A Sandman; Mohammed R Lenjavi; Tallie Z Baram
Journal:  Endocrinology       Date:  2008-06-19       Impact factor: 4.736

10.  Evidence of direct estrogenic regulation of human corticotropin-releasing hormone gene expression. Potential implications for the sexual dimophism of the stress response and immune/inflammatory reaction.

Authors:  N C Vamvakopoulos; G P Chrousos
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.